MSCs in Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1 SUPPL, 2011, Pages

  Horwitz, Edwin M ^a   Maziarz, Richard T ^b   Kebriaei, Partow ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ARTICLE; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; OUTCOME ASSESSMENT; PROPHYLAXIS; TISSUE REPAIR; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 78650637284     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.026     Document Type: Article

References (100)

1. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. Horwitz E., Le Blanc K., Dominici M., et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
3. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
4. Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
5. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2:83-92.
6. Owen M., Friedenstein A.J. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp 1988, 136:42-60.
7. Caplan A.I. Mesenchymal stem cells. J Orthop Res 1991, 9:641-650.
8. Caplan A.I., Bruder S.P. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 2001, 7:259-264.
9. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
10. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., Caplan A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
11. Horwitz E.M., Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit?. Cytotherapy 2008, 10:771-774.
12. Ponomaryov T., Peled A., Petit I., et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000, 106:1331-1339.
13. Peled A., Petit I., Kollet O., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
14. Majumdar M.K., Thiede M.A., Mosca J.D., Moorman M., Gerson S.L. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998, 176:57-66.
15. Honczarenko M., Le Y., Swierkowski M., Ghiran I., Glodek A.M., Silberstein L.E. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006, 24:1030-1041.
16. Wagner W., Feldmann R.E., Seckinger A., et al. The heterogeneity of human mesenchymal stem cell preparations-evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 2006, 34:536-548.
17. Tremain N., Korkko J., Ibberson D., Kopen G.C., DiGirolamo C., Phinney D.G. MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages. Stem Cells 2001, 19:408-418.
18. Wagner W., Wein F., Seckinger A., et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005, 33:1402-1416.
19. Kern S., Eichler H., Stoeve J., Kluter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24:1294-1301.
20. Garrett R.W., Emerson S.G. Bone and blood vessels: the hard and the soft of hematopoietic stem cell niches. Cell Stem Cell 2009, 4:503-506.
21. Haynesworth S.E., Barber M.A., Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166:585-592.
22. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98:1076-1084.
23. Väänänen H.K. Mesenchymal stem cells. Ann Med 2005, 37:469-479.
24. Cheng L., Qasba P., Vanguri P., et al. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J Cell Physiol 2000, 184:58-69.
25. Dazzi F., Ramasamy R., Glennie S., et al. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006, 20:161-171.
26. Caimi P.F., Reese J., Lee Z., et al. Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr Opin Hematol 2010, 17:505-513.
27. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
28. Li N., Feugier P., Serrurrier B., et al. Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity. Exp Hematol 2007, 35:507-515.
29. Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
30. Frassoni F.L.M., Bacigalupo A., Gluckman E., et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hemopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched pair analysis. Bone Marrow Transplant 2002, 29:75.
31. Ringdén O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
32. Parekkadan B., Milwid J.M. Mesenchymal stem cells as therapeutics. Annu Rev Biomed. Eng 2010, 12:87-117.
33. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009, 37:1145-1453.
34. Maggini J., Mirkin G., Bognanni I., et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010, 5:e9252.
35. Hemeda H., Jakob M., Ludwig A.K., et al. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. Stem Cells Dev 2010, 19:693-706.
36. Pulavendran S., Vignesh J., Rose C. Differential anti-inflammatory and anti-fibrotic activity of transplanted mesenchymal vs. hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice. Int Immunopharmacol 2010, 10:513-519.
37. Rathbun R.K., Faulkner G.R., Ostroski M.H., et al. Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells. Blood 1997, 90:974-985.
38. Pang Q., Keeble W., Christianson T.A., et al. FANCC interacts with Hsp70 to protect hematopoietic cells from IFN-gamma/TNF-alpha-mediated cytotoxicity. EMBO J 2001, 20:4478-4489.
39. Almeida-Porada G., Flake A.W., Glimp H.A., et al. Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Exp Hematol 1999, 27:1569-1575.
40. Anker P.S., Noort W.A., Kruisselbrink A.B., et al. Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2003, 31:881-889.
41. Maitra B., Szekely E., Gjini K., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33:597-604.
42. Angelopoulou M., Novelli E., Grove J.E., et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 2003, 31:413-420.
43. Fricke S., Ackerman M., Stolzing A., et al. Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment. PLos One 2009, 4:e6157.
44. Schriber J., Agovi M.A., Ho V., et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 2010, 16:1099-1106.
45. Koc O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
46. LeBlanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21:1733-1738.
47. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110:2764-2767.
48. MacMillan M.L., Blazar B.R., DeFor T.E., et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009, 43:447-454.
49. Baron F., Lechanteur C., Willems E., et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010, 16:838-847.
50. Fouillard L., Chapel A., Bories D., et al. Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. Leukemia 2007, 21:569-570.
51. Meuleman N., Tondreau T., Ahmad I., et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cell Dev 2009, 18:1249-1252.
52. Hu K.X., Sun Q.Y., Guo M., et al. The radiation protection and therapy effects of mesenchymal stem cells in mice with acute radiation injury. Br J Radiol 2010, 83:52-58.
53. Dainiak N., Ricks R.C. The evolving role of haematopoietic cell transplantation in radiation injury: potentials and limitations. BJR Suppl 2005, 27:169-174.
54. Kimura T., Asada R., Wang J., et al. Identification of long-term repopulating potential of human cord blood-derived CD34-flt3-severe combined immunodeficiency-repopulating cells by intra-bone marrow injection. Stem Cells 2007, 25:1348-1355.
55. Frassoni F., Gualandi F., Podestá M., et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008, 9:831-839.
56. Ramirez P.A., Wagner J.E., Brunstein C.G. Going straight to the point: intra-BM injection of hematopoietic progenitors. Bone Marrow Transplant 2010, 45:1127-1133.
57. Resnick I., Stepensky P., Elkin G., et al. MSC for the improvement of hematopoietic engraftment. Bone Marrow Transplant 2010, 45:605-606.
58. McNiece I., Harrington J., Turney J., et al. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy 2004, 6:311-317.
59. Robinson S.N., Ng J., Niu T., et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 2006, 37:359-366.
60. Zhang Y., Chai C., Jiang X.S., et al. Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells. Tissue Eng 2006, 12:2161-2170.
61. Dominici M., LeBlanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
62. Anjos-Afonso F., Bonnet D. Flexible and dynamic organization of bone marrow stromal compartment. Br J Haematol 2007, 139:373-384.
63. Khaldoyanidi S. Directing stem cell homing. Cell Stem Cell 2008, 2:198-200.
64. Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and a higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
65. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
66. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
67. Horwitz E.M., Le Blanc K., Dominici M., et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005, 7:393-395.
68. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
69. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
70. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
71. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
72. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
73. Ramasamy R., Tong C.K., Seow H.F., Vidyadaran S., Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 2008, 251:131-136.
74. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000, 28:875-884.
75. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105:93-98.
76. Horwitz E.M., Gordon P.L., Koo W.K., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002, 99:8932-8937.
77. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007, 213:341-347.
78. Bruder S.P., Jaiswal N., Haynesworth S.E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997, 64:278-294.
79. Auletta JJ CK, Solchaga LA, Deans RJ, vant Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: Current impact and future directions. Biol Blood Marrow Transplant. 2010;16:891-906.
80. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
81. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
82. Welniak L.A., Blazar B.R., Murphy W.J. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007, 25:139-170.
83. Keating A. How do mesenchymal stromal cells suppress T cells?. Cell Stem Cell 2008, 2:106-108.
84. Prevosto C., Zancolli M., Canevali P., Zocchi M.R., Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007, 92:881-888.
85. Sundin M., Barrett A.J., Ringden O., et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 2009, 32:755-764.
86. Li J, Zhu H, Liu Y, et al. Human mesenchymal stem cell transplantation protects against cerebral ischemic injury and upregulates interleukin-10 expression in Macaca fascicularis. Brain Res. 1334:65-72.
87. Devine S.M., Cobbs C., Jennings M., Bartholomew A., Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003, 101:2999-3001.
88. Chapel A., Bertho J.M., Bensidhoum M., et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003, 5:1028-1038.
89. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004, 95:9-20.
90. Prockop D.J., Olson S.D. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood 2007, 109:3147-3151.
91. Ball L., Bredius R., Lankester A., et al. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia 2008, 22:1256-1257.
92. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
93. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
94. Kurtzberg J., Prasad V., Grimley M.S., et al. Allogeneic himan mesenchymal stem cell therapy (Prochymal) as a rescue agent for severe treatment resistant GVHD in pediatric patients 2009, American Society of Blood and Marrow Transplantation, Orlando, Florida, S169.
95. von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
96. Muller I., Kordowich S., Holzwarth C., et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008, 40:25-32.
97. Fang B., Song Y., Zhao R.C., Han Q., Lin Q. Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc 2007, 39:1710-1713.
98. Prasad V.K., Lucas K.G., Kleiner G.I., et al. Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (Prochymal(TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2010, [Epub ahead of print].
99. Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
100. Martin B.J., Uberti J.P., Soiffer R.J., et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD 2010, Amercian Society of Bone Marrow Transplantation, Orlando, Florida, S169.